Is BIO.DE stock a buy after the 29 Jan 2026 pullback?

BIO.DE stock can be a tactical buy for short-term traders on an oversold bounce, but fundamentals show negative EPS and cash flow. Use a tight stop-loss and limit position size; long-term investors should wait for clearer profit recovery signals.

What are the main risks for BIO.DE stock right now?

Main risks include negative free cash flow per share **-1.87**, EPS **-0.63**, leverage with debt to equity **1.31**, and biotech sector volatility. Operational updates or plasma supply disruptions could widen downside quickly.

How does Meyka AI forecast affect a trading plan for BIO.DE stock?

Meyka AI's forecast model projects **€42.05** for one year, near current price, which suggests limited upside from here. Use the forecast as one input among technicals and fundamentals, not as a sole decision driver.

DE Stocks

BIO.DE Biotest AG €42.20 (XETRA) 29 Jan 2026: Oversold bounce as tactical entry

ByHuzaifa Zahoor January 30, 2026January 30, 2026

Biotest AG (BIO.DE) closed on XETRA in Germany at €42.20 on 29 Jan 2026, signaling a small pullback after a recent run near its year high. The setup reads like an oversold bounce: volume at 175.00 shares and relative volume 1.36 suggest active interest in a thin book. Traders watching BIO.DE stock can consider short-term entries while monitoring fundamentals such as EPS -0.63 and PE -66.98. Meyka AI’s research flags a mixed picture of solid liquidity and stretched valuation, so we frame this as a tactical trade, not a long-term buy thesis